Quinn William P. 4

What Happened William P. Quinn, President, CEO, CFO and a director of Bolt Biotherapeutics (BOLT), reported two transactions. He made a small open‑market/ESPP purchase of 125 shares on 2025-12-05 at $4.61 per share (about $576 total). He was also granted a 20,000-share option award on 2026-01-28 (reported as a derivative award with $0.00 per-share acquisition price at grant).

Key Details

• Open-market/ESPP purchase: 125 shares @ $4.61 on 2025-12-05 — ~$576 total. Footnote: acquired under the issuer’s Employee Stock Purchase Plan and exempt under Rule 16b‑3(c).
• Award/grant: 20,000 shares (derivative option) reported 2026-01-28 with $0.00 per-share acquisition price. Footnote: the option vests 1/36th each month of continuous service following January 1, 2026.
• Filing: Form 4 covering these transactions was filed 2026-02-04. This appears to be a late filing relative to the normal two-business-day Section 16 deadline for insider reporting.
• Shares owned after the transactions: not specified in the summary provided.

Context The purchase under an ESPP is a routine employee buy and is exempt under Rule 16b‑3(c). The 20,000-share item is a time‑vesting option award (no immediate cash paid) that vests monthly over three years — this is a compensation award, not an immediate sale. These types of grants are common for executives and do not by themselves indicate intent to buy or sell stock in the open market.